Supplementary Figure 3

A

Progression on Arm A or B

Control

ceritinib

*R

Rechallenge treatment

anti PD-1
+ceritinib

*R = randomization

B

Progression on

Arm A or B

Control

Rechallenge Treatment

ceritinib
anti-PD-1
micro-MRI

C

PFS^3

Survival (%)

0 20 40 60 80 100

0 10 20 30 40

Days

Rechallenge post-Arm A/B: 14 d (95% CI, 0.0-37.8)
Rechallenge control: 14 d (95% CI, 2.8-25.2)